728 x 90

Planatome’s Game-Changing $5m Series A Funding Signals a New Era in Biotech Innovation

Planatome’s Game-Changing $5m Series A Funding Signals a New Era in Biotech Innovation

Planatome’s recent funding round will enable the company to expand its innovative surgical blade technology and improve patient care.

Planatome, a medical device company, has successfully closed a $5 million Series A equity investment round, along with securing an additional $1 million convertible venture debt commitment. This funding will allow the company to hire top-level commercial talent, expand manufacturing capacity, and create new business lines using its proprietary polishing technology for various surgical cutting instruments.

The company’s chief financial officer, David Husband, expressed excitement about the funding, stating that it will fuel market activation and enable Planatome to reach more surgeons. During the early stages of the COVID-19 pandemic, when surgical procedures were delayed or canceled, the company utilized the time to refine its blade design. Now, with the investment in hand and positive feedback from surgeons, Planatome is well-prepared for rapid growth as the healthcare industry returns to normalcy.

Tim Tobin, the CEO of Planatome, highlighted the elegance and widespread appeal of the company’s technology. By removing jagged features that can damage tissue, Planatome’s blades promote improved healing responses. This stage in the company’s evolution will see Planatome expanding its reach and introducing highly refined products that set new standards of patient care on a global scale.

Planatome’s patented surface modification technology is based on chemical mechanical planarization, a process commonly used in advanced chip manufacturing. When applied in the medical field, this technology dramatically improves the surface smoothness of surgical blades by a factor of 1,000 or more. Surgeons who use Planatome blades have reported experiencing less soft tissue damage, less closing resistance, cleaner margins, and fewer complications. Additionally, patients benefit from reduced inflammation, less pain, and faster healing with minimal scarring. The blades have received approval for use in the United States and South Korea and have recently been approved by several hospitals and surgical centers.

Furthermore, Planatome plans to leverage its technology for other medical device applications, including surgical scissors, laparoscopic tools, and robotic end effectors. This expansion will allow the company to have a broader impact on improving patient outcomes and advancing surgical techniques.

In conclusion, Planatome’s recent funding round marks a significant milestone for the company as it continues to develop and expand its advanced surgical blade technology. With its innovative approach and focus on improving patient care, Planatome is poised to set new standards in the medical industry and push the boundaries of what is possible.

Avatar of Nayan Kumar
Nayan Kumar
CONTRIBUTOR
PROFILE